The ongoing Phase 1 clinical trial of the pan-RAS(ON) inhibitor AN9025 has reached a milestone as the first patient has received a dose in the intermittent weekly dosing (QW) arm. This is a significant development in the study involving the potential treatment, with important implications for testing the drug's efficacy and safety. The trial aims to assess the impact of AN9025 on patients, with a focus on dosing regimen and outcomes. This progress marks a step forward in the evaluation of the inhibitor's effects, setting the stage for further advancements in the research.
